News and Updates

CSPC Pharmaceutical secures NMPA approval for Goserelin sustained-release injection trials, aiming to advance hormone-sensitive cancer treatment in China.

The JST-018 orthopoxvirus antibody has officially entered Phase 1 clinical trials. Learn about the $123.9M DoD initiative to combat viral threats.

Mosliciguat moves to Phase 3 PHrontier trials after a 20% PVR reduction in the PHocus study. Learn what this means for the future of pulmonary care.

New proteomic aging clocks are redefining Phase 2a trial success. Learn how measuring biological age is becoming a standard for future clinical validation.

Nektar is set to release 24-week durability data for rezpegaldesleukin in alopecia areata. Discover how this IL-2 agonist impacts long-term hair regrowth.

BridgeBio Pharma is pivoting its BBO-8520 drug candidate toward combination therapies for second-line NSCLC to improve outcomes in KRAS-mutant lung cancer.

Novartis reports a significant setback as their new heart drug fails to meet primary endpoints in Phase 3 trials. Read the full analysis on this development.

Dr. Sumanta K. Pal identifies a critical gap in bladder cancer trial access, urging for more inclusive and decentralized research to improve patient care.

Labcorp strengthens its global clinical trial network through the acquisition of MLM Medical Labs, enhancing precision testing and trial logistics.

The FDA has approved daraxonrasib for metastatic pancreatic cancer. Learn how this targeted therapy is changing patient outcomes in clinical trials.